Cytotoxic and genotoxic effects of antihypertensives distributed in brazil by social programs: are they safe?

Publication date: Available online 9 August 2018Source: Environmental Toxicology and PharmacologyAuthor(s): Maria Fernanda de Moura Leão, Jonathaline Apollo Duarte, Patrícia Dutra Sauzen, Jacqueline da Costa Escobar Piccoli, Luís Flávio Souza de Oliveira, E. Michel Mansur MachadoAbstractHypertension, a chronic non-transmissible multifactorial condition, it is highly frequent in Brazil, affecting about 32.5% of the population over 25 years of age. It is characterized by the sustained increase in systolic and diastolic blood pressure levels above 140 mmHg and 90 mmHg, respectively. It is the major aggravating factor in cardiovascular complications and the appearance of other comorbidities. Aiming to promote greater adherence to treatment and improve the population's access to basic medicament, in 2004 the Federal Government created the Programa Farmácia Popular do Brasil (PFPB); partnership with private institutions that provides the population with medicament to control hypertension, free of charge or subsidized at up to 90% of the value. The PFPB distributes the anti-hypertensives atenolol, captopril, enalapril, hydrochlorothiazide, losartan and propranolol. In this way, this work aims to evaluate the genotoxic potential of antihypertensives in human lymphocytes and macrophages, since they are widely used drugs and with few studies about their genotoxicological safety. The tests were developed from cell cultures treated with five different antihypertensive concentrat...
Source: Environmental Toxicology and Pharmacology - Category: Environmental Health Source Type: research